Belantamab mafodotin is under clinical development by GSK and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to GlobalData, Phase II drugs for Diffuse Large B-Cell Lymphoma have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Belantamab mafodotin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Belantamab mafodotin overview
Belantamab mafodotin (Blenrep) is a B-cell maturation antigen (BCMA)-directed antibody is produced in a mammalian cell line (Chinese Hamster Ovary) using recombinant DNA technology. It is formulated as lyophilized powder for solution for intravenous route of administered. Blenrep is indicated for the treatment multiple myeloma of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
The drug candidate is under development for the treatment of relapsed or refractory plasmablastic lymphoma or ALK+ large B-cell lymphoma, relapsed or refractory AL amyloidosis, relapsed or refractory multiple myeloma, diffuse large B-Cell lymphoma. It was also under development for follicular lymphoma.
GSK is a healthcare company that focuses on developing, manufacturing and commercializing general medicines, specialty medicines and vaccines. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular, and urogenital, anti-bacterials, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.
For a complete picture of Belantamab mafodotin’s drug-specific PTSR and LoA scores, buy the report here.